1000802-34-5

Basic information

• Product Name: 1,3-Benzodioxol-5-aMine, 6-iodo-
• Synonyms: 1,3-Benzodioxol-5-aMine, 6-iodo-;6-iodobenzo[d][1,3]dioxol-5-aMine;6-Iodo-benzo[1,3]dioxol-5-ylamine
• CAS NO: 1000802-34-5
• Molecular Formula: C₇H₆INO₂
• Molecular Weight: 263.03251
• Mol File: 1000802-34-5.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 1,3-Benzodioxol-5-aMine, 6-iodo-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-Benzodioxol-5-aMine, 6-iodo-(1000802-34-5)
• EPA Substance Registry System: 1,3-Benzodioxol-5-aMine, 6-iodo-(1000802-34-5)

Safety Data

• Hazardous Substances Data: 1000802-34-5(Hazardous Substances Data)

Usage

General Description

1,3-Benzodioxol-5-amine, 6-iodo-, also known as 6-Iodo-MDA, is a chemical compound with the molecular formula C10H10INO2. It is a substituted amphetamine and a derivative of the popular recreational drug MDMA, which is also known as ecstasy. 6-Iodo-MDA is a psychoactive substance that has been studied for its potential use in therapy for anxiety, depression, and PTSD. It acts as a serotonin, norepinephrine, and dopamine releasing agent, leading to feelings of euphoria, increased empathy, and emotional openness. The compound is also known for its stimulating effects, including heightened energy, focus, and sociability. However, it is important to note that 6-Iodo-MDA is a controlled substance in many countries and can be highly dangerous and addictive when misused.

Upstream product

• 1000802-33-4 N-(6-iodobenzo[d][1,3]dioxol-5-yl)acetamide 
• 13067-19-1 3,4-methylenedioxyacetanilide 
• 14268-66-7 benzo[1,3]dioxolo-5-ylamine 

Downstream Products

• 106517-64-0 5,6-methylenedioxyindolyl-2-carboxylic acid 

Relevant articles and documents

Chelating Group Enabled Palladium-Catalyzed Regiodivergent Carbonylative Synthesis of 2,3-Dihydroquinolin-4(1H)-ones

A new procedure on palladium-catalyzed carbonylative cyclization of N-(2-pyridyl)sulfonyl (N-SO2Py)-2-iodoanilines with terminal alkenes has been developed for the rapid construction of dihydroquinolin-4(1H)-one scaffolds. Enabled by the chelat

Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94

Grp94 is involved in the regulation of a restricted number of proteins and represents a potential target in a host of diseases, including cancer, septic shock, autoimmune diseases, chronic inflammatory conditions, diabetes, coronary thrombosis, and stroke. We have recently identified a novel allosteric pocket located in the Grp94 N-terminal binding site that can be used to design ligands with a 2-log selectivity over the other Hsp90 paralogs. Here we perform extensive SAR investigations in this ligand series and rationalize the affinity and paralog selectivity of choice derivatives by molecular modeling. We then use this to design 18c, a derivative with good potency for Grp94 (IC50 = 0.22 μM) and selectivity over other paralogs (>100- and 33-fold for Hsp90α/β and Trap-1, respectively). The paralog selectivity and target-mediated activity of 18c was confirmed in cells through several functional readouts. Compound 18c was also inert when tested against a large panel of kinases. We show that 18c has biological activity in several cellular models of inflammation and cancer and also present here for the first time the in vivo profile of a Grp94 inhibitor.

FUSED AMINO PYRIDINES FOR THE TREATMENT OF BRAIN TUMORS

The present invention relates to the use of compounds with fused amino pyridine core for the treatment of malignancies associated with brain and lung. The oral administration of compounds of the instant application results in effective brain penetration and provides for non-intrusive treatment of brain and lung tumors.